Curcumin for Osteoporosis

Curcumin is not a proven treatment for osteoporosis, and no study has tested whether it prevents fractures. The most positive result is a double-blind trial of 60 postmenopausal women with osteoporosis: adding curcumin to alendronate for 12 months raised bone mineral density (BMD) at four sites more than alendronate alone (Khanizadeh 2018).

The larger trial is less encouraging. In 120 postmenopausal women with osteoporosis or osteopenia who were all taking alendronate, calcium and vitamin D, 80 mg of nanomicelle curcumin for 6 months did not lower bone turnover markers compared with placebo; after adjustment, only curcumin combined with Nigella sativa (black seed) oil lowered alkaline phosphatase (Kheiridoost 2022). The remaining human studies are weaker, and all the placebo-controlled osteoporosis trials come from two Iranian research groups. Bisphosphonates remain the first-line treatment for postmenopausal osteoporosis (Qaseem 2023).

Curcumin has antioxidant, anti-apoptotic (cell-protecting) and anti-inflammatory activity, and a 2023 review of preclinical studies found it helped maintain bone in several animal and cell models of osteoporosis; the authors said it still needs rigorous clinical trials (Yang 2023).

In the alendronate add-on trial, bone-specific alkaline phosphatase and CTx (a breakdown product of bone collagen, used as a marker of bone resorption) fell and osteocalcin rose more with curcumin plus alendronate than with alendronate alone (Khanizadeh 2018). In a small study of 26 people with MGUS (a blood plasma-cell disorder) taking 4 g of curcumin a day, 27% had a fall of more than 25% in urinary N-telopeptide, another resorption marker (Golombick 2009).

Animal models and blood markers are not fractures. When a 2022 meta-analysis pooled trials of curcumin and other herbs, it found no significant effect on bone-specific alkaline phosphatase, CTx, deoxypyridinoline or osteocalcin (Kheiridoost-Langaroodi 2022). In the largest curcumin trial, osteocalcin and osteopontin did not differ between groups (Kheiridoost 2022).

Curcumin also did not change a microRNA linked to bone metabolism: in what appears to be another report from the same Tabriz trial, only Nigella sativa, not curcumin, changed circulating miRNA-21 (Farshbaf-Khalili 2021).

The only osteoporosis trial that reports its dose used 80 mg of nanomicelle curcumin for 6 months (the abstract does not say how often), on top of alendronate 70 mg, calcium 500 mg and vitamin D 400 IU (Kheiridoost 2022). The alendronate add-on trial does not give the curcumin dose in its abstract (Khanizadeh 2018), the spinal cord injury trial prints it as "110/mg/kg/day", which cannot be read as a sensible dose (Hatefi 2018), and the low bone density pilot does not state it (Riva 2017).

Label reality matters: curcumin products vary in how much curcumin they contain, many add piperine from black pepper to raise absorption, and only conventional, not absorption-enhanced, curcumin is considered likely safe, for up to 2 or 3 months (NCCIH 2025). Nanomicelle curcumin, the form in the trials, is designed to raise absorption, and the trials ran 6-12 months, longer than that safety window. Bone density changes slowly, so the trial that found a gain measured it after 12 months (Khanizadeh 2018).

In a randomised, double-blind trial, 60 postmenopausal women with osteoporosis were split into three groups of 20: control, alendronate, and alendronate plus curcumin. After 12 months, BMD measured by DXA at the total body, total hip, lumbar spine and femoral neck rose significantly more with the combination than with alendronate alone or control; bone-specific alkaline phosphatase and CTx fell and osteocalcin rose at 6 months (Khanizadeh 2018).

The groups were small, the abstract does not give the curcumin dose or say what the control group received, and the result has not been repeated by another team.

This triple-blind trial randomised 120 women aged 50-65 with osteoporosis or osteopenia to placebo, 80 mg nanomicelle curcumin, 1,000 mg Nigella sativa oil, or both, for 6 months, on top of alendronate, calcium and vitamin D. Alkaline phosphatase fell compared with placebo in the Nigella sativa group (P = .029) and the combination group (P = .015), and after adjustment only the combination stayed significant (P = .004). Curcumin alone did not differ from placebo, and osteocalcin and osteopontin showed no between-group differences (Kheiridoost 2022).

The trial did not report bone density. A second paper with the same design, size, doses and authors, probably from the same trial, found that only Nigella sativa changed miRNA-21 (Farshbaf-Khalili 2021).

In 100 people with spinal cord injury, curcumin for 6 months raised lumbar, femoral neck and hip BMD while they fell with placebo; at the end, femoral neck BMD was 0.718 vs 0.712 g/cm² and total hip BMD 0.742 vs 0.692 g/cm² (Hatefi 2018). The abstract does not describe randomisation, and three of its authors also ran the alendronate add-on trial.

In a non-randomised pilot, 57 otherwise healthy adults with low bone density chose standard management with or without a lecithin-bound turmeric supplement. After 24 weeks, heel ultrasound transmission values fell 21.0% from baseline (which the authors read as higher density) and finger and jaw density rose 7.1% and 4.8% in the supplement group, with no change in controls (Riva 2017). Heel ultrasound is not the DXA hip and spine measurement used to diagnose osteoporosis.

A 2022 meta-analysis of five herbal medicines (16 studies, 968 participants; 10 pooled) found no significant effect on bone turnover markers, but curcumin significantly increased total hip BMD (P < 0.001), with high heterogeneity overall (Kheiridoost-Langaroodi 2022). A 2025 systematic review of 12 trials in postmenopausal women described conflicting reports on bone density markers (Akyakar 2025), and a 2025 meta-analysis of 14 trials that grouped bone health among its outcomes reported significant effects only on blood pressure, antioxidant markers, AST and vasomotor symptoms (Jin 2025).

Missing: any fracture outcome, trials in men with primary osteoporosis, trials of curcumin without a bisphosphonate in postmenopausal osteoporosis, and replication outside the two Iranian groups in Ilam and Tabriz. Proven fracture prevention comes from medication plus adequate calcium and vitamin D, weight-bearing and resistance exercise, no smoking, limited alcohol and fall prevention (LeBoff 2022).

In the 6-month nanomicelle trial, liver enzymes, urea and creatinine showed no toxicity at 80 mg (Kheiridoost 2022). Standard curcumin is likely safe in recommended amounts for up to 2 or 3 months and can cause nausea, reflux, diarrhoea or constipation; liver damage has been reported with high-absorption formulations, and turmeric supplements may be unsafe in pregnancy (NCCIH 2025).

The US Drug-Induced Liver Injury Network found 10 turmeric-related cases: injury typically appeared after 1 to 4 months, 5 people were hospitalised and 1 died, 3 of the 7 products tested also contained piperine, and 7 patients carried the gene variant HLA-B*35:01 (Halegoua-DeMarzio 2023).

Both osteoporosis trials gave curcumin with alendronate, and the larger one also with calcium and vitamin D, without reported toxicity (Kheiridoost 2022). A 10-day study of a lecithin-bound curcumin found no change in INR on warfarin or dabigatran or in bleeding time on antiplatelet drugs (Hu 2018), but it was short. A family-medicine review lists curcumin among supplements that may interact with a few medicines (Asher 2017). Timing matters with alendronate itself: its label says to take it with plain water at least 30 minutes before the first food, drink or medicine of the day, and calcium supplements interfere with its absorption, so other oral medicines should wait at least half an hour (FDA 2026).